Health Research 2027 proposal to


TITLE: Preclinical validation of a TCR variable region-targeting immunotherapy platform for aggressive mature T-cell leukemias and lymphomas

 


RESEARCH CONSORTIUM

Organization, Name, Role

1- Agencia Estatal Consejo Superior de Investigaciones Científicas, M.P., Balbino Alarcón, Project Leader

2- Fundación para la Inv. Biomédica del Hospital Univ. 12 de Octubre and UCM, Joaquín Martínez, Principal Investigator. José R. Regueiro, Team Member.

3- Fundació Institut de Recerca Contra la Leucèmia Josep Carreras, Pablo Menéndez, Principal Investigator. Pablo Engel, Team Member.

4- AEAL, Asociación Española de Afectados por Linfoma, Mieloma y Leucemia, Begoña Barragán, Civil Society Organisation Contact

5- AELIC - Asociación Española de Pacientes con Linfoma Cutáneo, Almudena Montejo, Civil Society Organisation Contact


Lay summary

Mature T-cell malignancies are rare, aggressive blood cancers with limited treatment options and poor survival. Unlike B-cell malignancies, they are difficult to treat with immunotherapy because targeting cancerous T cells can also destroy healthy T cells, causing severe immunodeficiency. This project aims to develop precision immunotherapies that selectively eliminate malignant T cells while preserving protective immunity. By targeting specific variable regions of the T-cell receptor, which identify individual T-cell populations, we will develop a platform of targeted therapies tailored to each patient's cancer. These approaches will be evaluated in laboratory studies and relevant animal models, advancing promising candidates toward clinical testing. Ultimately, this platform could provide new treatment options for patients with mature T-cell malignancies who currently have few effective alternatives.


Scientific Abstract

Mature T-cell lymphomas and leukemias (TCLs) remain aggressive malignancies with poor clinical outcomes and limited treatment options. Unlike B-cell malignancies, TCLs lack effective targeted immunotherapies because depletion of healthy T cells can cause profound immunodeficiency, with no established rescue strategy. There is therefore a critical need for precision therapies that selectively eradicate malignant T cells while preserving protective immunity. Our strategy exploits T-cell receptor (TCR) variable (V) regions as tumoral targets. Whereas each V region is expressed by just a small fraction of healthy αβ T cells, malignant T cells express a single clonal TCR V region. We aim to establish a modular platform for developing V-region-directed chimeric antigen receptor (CAR)-T cells and antibody-drug conjugates (ADCs), specific for the patient's malignant TCR V region. Antibodies, ADCs and CAR constructs will be developed as off-the-shelf products. Our preliminary data show that Vβ3-specific CAR-T cells selectively eliminate Vβ3⁺ leukemic cells while sparing more than 98% of the healthy T-cell repertoire. In a cohort of nine patients with Sézary syndrome, three have malignant cells expressing the Vβ5.4 region. Consequently, we have generated monoclonal antibodies against Vβ5.4 and are currently developing corresponding CAR and ADC candidates. This project will advance the Vβ3 and Vβ5.4 programs towards clinical readiness by building appropriate animal models, while expanding the range of targetable TCR V families and validating a scalable development platform. Our goal is to build a portfolio of off-the-shelf antibody-based therapies and complementary CAR-T products with the potential to cover most TCL patients. This approach could establish a new precision immunotherapy paradigm that selectively targets malignant T-cell clones while preserving T-cell mediated immunity.